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Rescue of Pressure Overload-Induced Heart Failure by Estrogen
Therapy
Andrea Iorga, PhD; Jingyuan Li, MD, PhD; Salil Sharma, PhD; Soban Umar, MD, PhD; Jean C. Bopassa, PhD;* Rangarajan D. Nadadur, BS;
Alexander Centala, BS; Shuxun Ren, MD; Tomoaki Saito, PhD;† Ligia Toro, PhD; Yibin Wang, PhD; Enrico Stefani, MD, PhD;
Mansoureh Eghbali, PhD
Background-—Estrogen pretreatment has been shown to attenuate the development of heart hypertrophy, but it is not known
whether estrogen could also rescue heart failure (HF). Furthermore, the heart has all the machinery to locally biosynthesize
estrogen via aromatase, but the role of local cardiac estrogen synthesis in HF has not yet been studied. Here we hypothesized that
cardiac estrogen is reduced in HF and examined whether exogenous estrogen therapy can rescue HF.
Methods and Results-—HF was induced by transaortic constriction in mice, and once mice reached an ejection fraction (EF) of
35%, they were treated with estrogen for 10 days. Cardiac structure and function, angiogenesis, and fibrosis were assessed, and
estrogen was measured in plasma and in heart. Cardiac estrogen concentrations (6.181.12 pg/160 mg heart in HF versus
17.791.28 pg/mL in control) and aromatase transcripts (0.190.04, normalized to control, P<0.05) were significantly reduced
in HF. Estrogen therapy increased cardiac estrogen 3-fold and restored aromatase transcripts. Estrogen also rescued HF by
restoring ejection fraction to 53.11.3% (P<0.001) and improving cardiac hemodynamics both in male and female mice. Estrogen
therapy stimulated angiogenesis as capillary density increased from 0.660.07 in HF to 2.830.14 (P<0.001, normalized to
control) and reversed the fibrotic scarring observed in HF (45.52.8% in HF versus 5.31.0%, P<0.001). Stimulation of
angiogenesis by estrogen seems to be one of the key mechanisms, since in the presence of an angiogenesis inhibitor estrogen
failed to rescue HF (ejection fraction=29.32.1%, P<0.001 versus E2).
Conclusions-—Estrogen rescues pre-existing HF by restoring cardiac estrogen and aromatase, stimulating angiogenesis, and
suppressing fibrosis. ( J Am Heart Assoc. 2016;5:e002482 doi: 10.1161/JAHA.115.002482)
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H eart failure (HF) is often preceded by heart hypertrophy,which is usually triggered by external stressors. While
heart hypertrophy is presumed to be compensatory at the
beginning, it often progresses to chronic HF when insults
persist.1 Advanced chronic HF is most often treated with
aggressive nonpharmacological therapies such as heart
transplantation or implantable left ventricular assist devices.
Effective pharmacological therapies for treatment of HF
patients would possess major advantages because of their
noninvasive and more cost-effective nature. Several agents
such as a phosphodiesterase 5A inhibitor as well as the Gbc
small molecule inhibitor gallein have been shown to halt the
progression of cardiac remodeling and failure.2–4 However,
effective pharmacological intervention that can rescue HF at
an advanced stage is still necessary.
The heart has all the machinery for local biosynthesis of
estrogen via the help of aromatase. However, it is not known
whether local heart E2 biosynthesis is disrupted in HF. In
addition, estrogen pretreatment has been shown to attenuate
the development of heart hypertrophy,5 but it is not known
whether E2 could rescue advanced HF. Here we found that HF
induced by pressure overload is associated with lower local
heart (but not plasma E2) concentrations, and that cardiac
aromatase transcripts were significantly downregulated in HF.
We hypothesized that local heart E2 concentration is reduced
in HF possibly because of the downregulation of cardiac
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aromatase, and therefore exogenous E2 therapy after the
onset of advanced HF may rescue pre-existing HF. We now
show that short-term E2 therapy starting after the onset of
advanced HF restores cardiac hemodynamics and the ejection
fraction from 35% in HF to 55%. We demonstrate that the
beneficial effects of E2 seem to result from the interplay of
various factors, including stimulation of angiogenesis and
suppression of fibrosis.
Methods
Animals
Wild-type male and female CD-1 and male C57Bl/6 mice 3 to
4 months old were used. All protocols received institutional
review and committee approval from the Division of Labora-
tory Animal Medicine of UCLA.
Experimental Protocol
Healthy mice with an ejection fraction of 60% were
randomly subjected to sham or transaortic constriction
(TAC) surgery as described previously.6 Serial echocardiogra-
phy was performed to monitor the heart structure and
function throughout the course of the experiment. HF was
achieved 6 to 8 weeks after the TAC surgery with an ejection
fraction of 35%. Once TAC mice reached HF, mice were
randomly euthanized (HF group), or were assigned to one of
the following treatment groups for 10 days: E2 via a
subcutaneous 10-day continuous-release pellet of 0.03 mg
E2/kg per day (Innovative Research of America, E2-RES
group), the angiogenesis inhibitor TNP-470 (30 mg/kg,
Sigma, once every other day) alone, TNP-470 together with
E2 pellets (E2+TNP), or placebo pellets (containing 5
compounds: cholesterol, lactose, cellulose, phosphates, and
cerates, which were used as vehicle for E2).
Plasma and Heart Estrogen Measurements
Plasma and heart E2 measurements were performed using the
estradiol enzyme immunoassay (Cayman Chemical). Plasma
measurements were conducted according to manufacturer’s
protocol. For determining estrogen concentrations from the
heart, hearts were first frozen and powdered with a mortar
and pestle. Eighty milligrams powdered heart tissue was
weighed from each heart, lysed in estradiol enzyme
immunoassay buffer, and sonicated in a total volume of
500 lL estradiol enzyme immunoassay buffer. This lysate was
then subjected to standard estradiol enzyme immunoassay
procedure according to manufacturer’s protocol and the
concentration values were obtained were based on a standard
curve in units of pg/mL. As each 500 lL lysate sample
contained 80 mg of heart tissue, 1 mL of lysates would
contain 160 mg of heart tissue. The concentration values are
thus expressed as pg/160 mg heart.
Cardiac Hemodynamics
Serial B-Mode and M-Mode echocardiography was performed
using a VisualSonics Vevo 2100 equipped with a 30-MHz linear
transducer to accurately monitor the stage of the disease by
measuring cardiac hemodynamic parameters and assessing
heart structure.7 The left ventricular (LV) ejection fraction, LV
wall thickness, and LV cavity dimensions were quantified using
M-mode. The left ventricular systolic pressure (LVSP), left
ventricular end-diastolic pressure (LVEDP), and heart rate (HR)
were recorded directly by inserting a catheter (1.4F Millar SPR-
671) connected to a pressure transducer (Power Lab, ADInstru-
ments) into the LV right before euthanizing. The left ventricular
developed pressure (LVDP) and rate pressure product (RPP)
were calculated as LVDP=LVSP –LVEDP, RPP=HR9LVDP. The
maximum rate of the LV pressure rise (dP/dtmax) and decline
(dP/dtmin) were directly calculated from the recordings.
Real-Time Quantitative Polymerase Chain
Reaction (RT-qPCR)
For RT-qPCR quantification, hearts were excised and rinsed in
ice-cold phosphate-buffered saline. The heart weight was
measured, the atrias were then removed, and the ventricles
were snap-frozen in liquid nitrogen and stored at 80°C. For
RNA extraction, hearts were powdered with a mortar and
pestle on dry ice, suspended in 2 mL Trizol (Invitrogen), and
homogenized with a Polytron (Kinematica). RNA quality was
assessed via gel electrophoresis. For cDNA synthesis, RNA
concentration was assessed using a spectrophotometer
(Beckman) and 2 lg of RNA with purity (A260/A280) of 1.7
to 2.0 were reverse transcribed using the Omniscript RT kit
(Qiagen) according to manufacturer’s protocol in a final
reaction volume of 20 lL. The real-time qPCR was performed
using IQ SYBR Green supermix (BioRad) according to manu-
facturer’s protocol in a final volume of 25 lL using a BioRad
CFX RT-qPCR machine. For all assays, there were at least 3
samples/group assayed in duplicate. Threshold cycle (Cq
value) was determined using CFX Manager, and the Cq value
of the gene of interest was normalized to the Cq value of its
own internal control gene (GAPDH). Controls consisted of: the
reaction cocktail without reverse transcriptase and H2O
instead of cDNA tested by RT-qPCR.
RT-qPCR Primer Validation
Prior to the RT-qPCR experiments, each primer set was
validated to ensure that it yields a single sharp peak in the
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RT-qPCR melting curve. Primer sequences are listed in
Table 1. The controls for each primer set consisted of the
reaction cocktail without reverse transcriptase and H2O
instead of cDNA tested simultaneously by RT-qPCR. All the
RT-qPCR products, including the negative controls, were then
subjected to gel electrophoresis to ensure amplification of a
single product of the expected molecular size without any
product amplified in the negative control reactions.
Immunochemistry and Imaging
Whole hearts were fixed in 4% paraformaldehyde and
transversal 6 to 7 lm sections were obtained with a cryostat.
Tissue sections were used for standard eosin/hematoxylin
and Masson’s Trichrome (Sigma) staining according to
manufacturer’s protocol and images were acquired with a
light microscope (Nikon). For immunofluorescent confocal
microscopy, sections were labeled with anti-CD-31 (04-1074;
Millipore, 1:200 dilution) and wheat germ agglutinin (Invitro-
gen, 1:500 dilution) and images were acquired with a confocal
scanning microscope (Nikon).
Western Blot
Whole heart cell lysates were prepared by homogenizing the
hearts in 50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl,
0.5% deoxycholate, 1% NP-40, 0.1% sodium dodecyl sulfate,
1 mmol/L EGTA, and 1 mmol/L EDTA supplemented with
Phosphatase and Protease Inhibitor cocktails (Roche). The
samples were then centrifuged at 12 000g for 10 minutes and
the supernatants were collected. The protein concentrations
were measured and 50 lg of protein were treated with sodium
dodecyl sulfate/dithiothreitol loading buffer prior to gel elec-
trophoresis. The blotswere probedwith anti-ERa (sc-542, Santa
Cruz Biotechnology), -ERb (sc-53494, Santa Cruz Biotechnol-
ogy), -Stat3 (#9139, Cell Signaling), -pStat3 (Y705, #9145, Cell
Signaling), -Akt (sc-8132, Santa Cruz Biotechnology), -pAkt
(Ser473, #4051, Cell Signaling), -GAPDH (NB300-327, Novus
Biologicals), and -Vinculin (V9131, Sigma-Aldrich). Quantifica-
tion of protein levels was achieved using Adobe Photoshop.
Statistical Analysis
Means of normally distributed measures were compared on
the appropriate scale across groups using the fixed-effects
ANOVA model assuming equal variances or allowing nonequal
variances as appropriate. For the nonequal variance models,
we conservatively estimate error degrees of freedom using
the Satterthwaite correction. Normality was evaluated by
examining residual error quantile–quantile plots and the
corresponding Shapiro–Wilk test under the above models.
Constant variance was evaluated by examining plots of the
residual errors versus the means under the above models.
Variables that did not follow the normal distribution were
compared across groups nonparametrically using the
Kruskal–Wallis test. Post hoc comparisons were adjusted for
multiple testing using the Holm criterion. The Holm criterion
states that the kth ordered P-value must be <0.059(k/3) if
the overall type I error is to be <0.05 for a given outcome.
Results
Local Heart Estrogen and Cardiac Aromatase
Expression Levels Are Significantly Lower in HF
Mice
Figure 1A demonstrates that plasma estrogen concentrations
remained unchanged in HF (26.296.10 pg/mL in HF and
27.434.27 pg/mL in control [CTRL]). Interestingly, however,
the local estrogen concentrations in the heart tissue were
significantly lower in HF compared to CTRL (6.181.12 pg/
160 mg of heart tissue versus 17.791.28 pg/160 mg of
heart in CTRL, Figure 1B). Additionally, cardiac aromatase
transcript levels were also 5-fold lower in HF compared to
Table 1. Real-Time Polymerase Chain Reaction Primer
Sequences
Gene Primer Sequences
GAPDH Forward: 50-CCTGCACCACCAACTGCTTAG -30
Reverse: 50-ATGACCTTGCCCACAGCCTTG -30
b-MHC Forward: 50-CTCAACTGGGAAGAGCATCCA -30
Reverse: 50-CCTTCAGCAAACTCTGGAGGC-30
Vegfa Forward: 50-ACACGGTGGTGGAAGAAGAG -30
Reverse:50-CAAGTCTCCTGGGGACAGAA -30
HifIa Forward: 50-TCAGTGCACAGAGCCTCCT -30
Reverse: 50- GCGGAGAAAGAGACAAGTCC -30
TGF-b1 Forward: 50-CCTGCAAGACCATCGACATGG-30
Reverse: 50-TGGTTTTCTCATAGATGGCGTT-30
Fibrosin 1 Forward: 50-AACACGAACCCTGAGCTGCCA-30
Reverse: 50-TCATGTAAGCCACACGAACGTG-30
Collagen I Forward: 50-GACCGATGGATTCCCGTTCGA-30
Reverse: 50- AAGGTCAGCTGGATAGCGACAT -30
Collagen III Forward: 50-AATTCTGCCACCCCGAACTCAA-30
Reverse: 50-TCCATCTTGCAGCCTTGGTTAG -30
LOX Forward: 50-CACGCAGCAGCAGAATGGGC -30
Reverse: 50-CGCAGTACCAGCCTCAGCGA-30
ANF Forward: 50-CTGATGGATTTCAAGAACCTGCT- 30
Reverse: 50-CTCTGGGCTCCAATCCTGTC-30
SERCA Forward: 50-CCTTCTACCAGCTGAGTCATTT-30
Reverse: 50-CAGATGGAGCCCACGAGCCA-30
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CTRL (0.190.04 in HF, normalized to CTRL, Figure 1C).
Estrogen therapy increased cardiac and plasma E2 concen-
trations to similar levels (61.463.75 pg/160 mg of heart
and 66.489.65 pg/mL, Figure 1A and 1B), and restored
aromatase transcripts to CTRL (0.950.08, normalized to
CTRL, Figure 1C).
We then explored whether exogenous treatment of estrogen
could rescue pre-existing HF. Figure 2A illustrates a typical
example of an M-mode echocardiogram from the same male
mouse at the baseline before the TAC operation (Baseline), and
in HF before and after E2 treatment. E2 therapy restored the
ejection fraction of HF mice in a surprisingly efficient manner
from 33.21.1% in HF to 53.11.3% within 10 days of E2
treatment (Figure 2B). As expected, HF was associated with a
significant increase in LV posterior wall thickness when
compared to CTRL, and E2 therapy did not affect this parameter
as it remains unchanged versus HF (Figure 2C). The cardiac
function of the HF mice treated with placebo progressively
declined. Some placebo-treated mice either died or were
euthanized because of poor health before the end of the 10-day
treatment period according to the criteria for early experiment
termination and euthanasia at UCLA, while others survived with
placebo for 10 days with worsening cardiac function.
E2 was also able to rescue cardiac function in C57/BL6
mice, the most common strain used for TAC studies, to similar
levels as CD-1 mice (data not shown). Furthermore, E2
therapy was also able to restore cardiac function in female
mice. Intact age-matched female mice were subjected to TAC
and once the ejection fraction reached 35%, estrogen
therapy was commenced at the same dose as in male mice
for 10 days. Figure 3 demonstrates that E2 was able to
rescue the myocardial contractility of female mice with HF
just as in male mice (55.352.78% with E2, 31.660.15% in
HF versus 65.531.24% in CTRL).
E2 partially reversed LV structural morphology changes
occurring in HF as reflected in the whole heart (Figure 4A) and
eosin/hematoxylin images (Figure 4B), as well as in the heart
weight to body weight ratio (mg/g: 5.390.14 CTRL;
10.150.3 HF, and 7.880.44 in E2-RES, Figure 4C). E2
therapy also decreased the cardiomyocyte cross-sectional
diameter by 10% (10.01 in CTRL versus 1.730.04 in HF
to 1.530.02 in E2, normalized to CTRL, Figure 4D). In
pathological heart hypertrophy, fetal genes such as b myosin
Figure 1. Local heart E2 concentrations and cardiac aromatase
transcripts are reduced in HF. A, Estrogen concentrations in plasma
and (B) in heart (n=6–13 mice/group) in control (CTRL) and after
treatment with E2 (E2-RES). C, Relative transcript expression of
cardiac aromatase normalized to CTRL. GAPDH was used as an
internal control (n=4–5 hearts/group). *P<0.05 vs CTRL;
**P<0.001 vs CTRL; ^^P<0.001 vs HF. CTRL indicates control;
E2-RES, E2-induced rescue; HF, heart failure.
Figure 2. Estrogen therapy rescues HF in male mice by
restoring heart function. A, Examples of M-mode images of the
parasternal short axis view by echocardiography from the same
mouse before TAC (Baseline), after TAC in HF, and after treatment
with E2 (E2-RES). B, Averaged EF in CTRL (black diamond), HF (red
circle) and after E2 treatment as a function of time (purple
squares). C, Left ventricular posterior wall thickness (LVPW) at the
end of diastole (filled bars) and systole (empty bars). Values and
the number of animals are given in Table 2. **P<0.001 vs CTRL.
CTRL indicates control; EF, ejection fraction; HF, heart failure;
TAC, transaortic constriction.
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heavy chain (b-MHC), atrial natriuretic factor (ANF), and
sarcoplasmic reticulum Ca2+ -ATPase (SERCA) are known to
be regulated.8,9 In HF, both b-MHC and atrial natriuretic factor
were greatly upregulated. b-MHC was upregulated 16-fold
from 1.000.24 in CTRL to 16.262.44 in HF (normalized to
CTRL), while atrial natriuretic factor was upregulated 10-fold
to 10.901.15 versus 1.000.23 in CTRL. E2 therapy
restored b-MHC levels similar to CTRL and significantly
downregulated atrial natriuretic factor to 4.090.24 (Fig-
ure 4E and 4F). SERCA was significantly downregulated in HF
(from 1.000.08 in CTRL to 0.560.12 in HF), and partially
restored to 0.720.09 with E2 (Figure 4G).
Stimulation of Cardiac Angiogenesis by E2
Therapy Is a Key Mechanism in E2-Induced
Rescue of HF
Reduced cardiac angiogenesis in HF has been previously
reported.10,11 Thus, we examinedwhether stimulation of cardiac
angiogenesis by E2 could be one of the mechanisms participat-
ing in the E2-induced rescue of HF. The transcript levels of 2
angiogenic markers, vascular endothelial growth factor (VEGF)
and hypoxia-inducible factor-1a (HIF1a), were both significantly
downregulated (5-fold) in HF mice. E2 treatment was not only
able to reverse the downregulation of VEGF andHIF1a transcript
levels, but also upregulated both transcripts3-fold higher than
in healthy controls (3.240.1 in E2 versus 0.260.06 in HF,
Figure 5A). Quantification of capillary density also revealed that
E2 therapy significantly enhanced capillary density compared to
the HF group (2.830.14 in E2 versus 0.660.07 in HF,
normalized to CTRL, Figure 5B and 5C). To further confirm the
role of angiogenesis in the E2-induced rescue of HF, HF mice
were treated with the angiogenesis inhibitor TNP-470 alone or
together with E2 (E2+TNP, Figure 5D). All the HF animals
Figure 3. Estrogen therapy rescues HF in female mice. A,
Examples of M-mode images of the parasternal short axis view by
echocardiography from the same mouse before TAC (Baseline),
after TAC in HF, and after treatment with E2. B, Averaged EF in
CTRL (black diamond), HF (red circle) and after E2 treatment (E2-
RES) as a function of time (purple squares). C, Left ventricular
posterior wall thickness (LVPW) at the end of diastole (filled bars)
and systole (empty bars). **P<0.001 vs CTRL. CTRL indicates
control; EF, ejection fraction; E2-RES, E2-induced rescue; HF,
heart failure; TAC, transaortic constriction.
Figure 4. E2-induced rescue of HF is associated with a
decreased heart weight to body weight ratio, decreased cardiomy-
ocyte diameter, and reversed expression of fetal gene transcripts.
A, Images of the whole heart as well as (B) hematoxylin and eosin
staining of cross-sections and longitudinal sections of hearts in
CTRL, HF, and E2-RESC. C, The heart weight to body weight ratio
(HW/BW, n=6–9 animals per group). D, Cardiomyocyte cross-
sectional diameter (CSD, normalized to CTRL). Relative transcript
expression of (E) b-MHC, (F) atrial natriuretic factor (ANF), and (G)
SERCA normalized to CTRL. GAPDH was used as an internal
control and its transcripts were similar in all conditions. *P<0.01
vs CTRL **P<0.001 vs CTRL; ^^P<0.001 vs HF; ^P<0.05 vs HF
(n=3–5 animals/group). CTRL indicates control; E2-RES, E-2
induced rescue; HF, heart failure; b-MHC, b-myosin heavy chain;
SERCA, sarcoplasmic reticulum Ca2+ -ATPase.
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treated with TNP-470 alone died shortly after commencing
treatment. E2 failed to rescue HF in the presence of TNP-470 as
ejection fraction (29.32.1%) was not significantly improved by
10 days of E2 therapy (Figure 5D). TNP-470 also prevented E2
from stimulating the capillary density (0.530.07 in E2+TNP
versus 2.830.14 in E2, Figure 5C). Next, we assessedwhether
exogenous estrogen could promote cardiac angiogenesis in
healthymice, in the absence of TAC. Figure 6 demonstrates that
in the absence of TAC stimulus, E2 was also able to significantly
induce cardiac angiogenesis by about 30% in healthy mice.
Estrogen Reverses HF-Induced Myocardial
Fibrosis
Extensive myocardial fibrosis has been identified in both severe
HF patients as well as in different experimental models of HF.12
Masson’s Trichrome staining revealed that the interstitial and
perivascular fibrosis observed in HF was absent in E2-treated
mice (Figure 7A). Mice in HF had 45.52.8% fibrous tissue in
cardiac sections versus 1.20.4% in CTRL, while E2 therapy
significantly decreased fibrotic scarring to 5.31.0% in E2
(Figure 7B). RT-PCR revealed that the transcript levels of
several profibrotic markers were significantly upregulated in HF
(from 1.00.2 to 1.80.1 for collagen I; 1.00.2 to 1.50.1
for collagen III; 1.00.9 to 4.30.6 for transforming growth
factor-b1; 1.00.5 to 3.60.2 for fibrosin I and 1.00.3 to
2.90.3 for lysil oxidase), while E2 treatment restored these
transcripts to levels comparable to the CTRL group (Figure 7C).
Estrogen-Induced Cardioprotection Is Associated
With Activation of Protein Kinase B Pathway and
Estrogen Receptor-b
It has previously been shown that E2 protects the heart via
regulation of the protein kinase B (Akt) and Stat3 path-
ways.13,14 While Stat3 is not regulated in our model in
Figure 5. Stimulation of cardiac angiogenesis by E2. A, Relative transcript expression of HIF1a and VEGF
normalized to CTRL. GAPDH was used as an internal control and its transcripts were similar in all
conditions. B, Single confocal images of LV sections immunostained for CD-31 (green, left panels), the
overlay of CD31 and wheat germ agglutinin WGA (red, middle panels) and at higher display magnification of
the white squares (right panels). C, Quantification of capillary density as microvessels per cardiomyocyte. D,
EF% at the end of the experiment. *P< 0.01 **P<0.001 vs CTRL; ^^P<0.001 vs HF; §§P<0.001 vs E2 (n=3–4
hearts/group). CTRL indicates control; EF, ejection fraction; E2-RES, estrogen rescue; HF, heart failure; LV,
left ventricular; VEGF, vascular endothelial growth factor.
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advanced HF and after E2 rescue (Figure 8A and 8B), Akt
phosphorylation is reduced approximately by half in HF (from
1.000.15 in CTRL to 0.550.08 in HF, normalized to CTRL),
while E2 therapy normalized phospho-Akt expression to CTRL
levels (1.140.15 with E2 rescue, Figure 8C and 8D).
As E2 mainly acts through its classical receptors ERa and/
or ERb, which are both present in the heart,15 we investigated
the ERa and ERb expression in HF and with E2 rescue. Both ERa
and ERb transcript and protein levels remain unchanged in HF,
while E2 treatment interestingly resulted only in increased ERb
protein expression from 1.000.08 in CTRL and 1.030.07 in
HF to 1.290.07 with E2 (normalized to CTRL, Figure 9).
E2 Therapy Restores Cardiac Hemodynamic
Parameters of HF Mice
Direct catheterization revealed that LVDP was reduced in HF
from 97.82.6 mm Hg in CTRL to 86.22.7 mm Hg in HF.
Consistent with the improvement of mechanical performance
of the heart after E2 therapy, LVDP also increased to
1314.6 mm Hg (Table 2). E2 also improved the RPP from
36 251.93531.7 mm Hg9beats/min in HF to 65 455
5533 mm Hg9beats/min after E2 treatment, Figure 10A).
The contractile and relaxation defects induced by HF were
also corrected by E2 therapy, as the maximum rate of LV
pressure rise (dP/dtmax) and decline (dP/dtmin) were restored
with E2 treatment to values similar to healthy hearts in spite
of the sustained presence of the TAC stress stimulus
(Figure 10B, Table 2). As expected, RPP and dP/dt could
not be restored by E2 in the presence of the angiogenesis
inhibitor TNP-470 (Figure 10).
Discussion
HF is a multifactorial and multiphase disease with a
major impact on human health. Despite the advances in
Figure 6. Stimulation of cardiac neoangiogenesis by E2 in the
absence of TAC in healthy mice. A, Single confocal images of LV
sections immunostained for CD31 (green, left panels), the overlay
of CD31 and WGA (red, middle panels) and at higher display
magnification of the white squares (right panels). B, Quantification
of capillary density as microvessels per cardiomyocyte. *P<0.05
vs CTRL (n=4 hearts/group). CTRL indicates control; LV, left
ventricular; TAC, transaortic constriction; E2-TREAT, estrogen
treatment group; WGA, wheat germ agglutinin.
Figure 7. E2-induced rescue of HF is associated with suppres-
sion of fibrosis. A, Representative Masson’s Trichrome staining of
LV sections (interstitial, top panels; perivascular, lower panels). B,
Quantification of overall fibrosis expressed as percentage of each
high-power field. C, Relative transcript expression of profibrotic
genes normalized to CTRL. GAPDH was used as an internal
control and its transcripts were similar in all conditions. *P<0.05
vs CTRL; **P<0.001 vs CTRL; ^P<0.05 vs HF; ^^P<0.001 vs HF
(n=3–5 hearts/group). CTRL indicates control; E2-RES, estrogen
rescue; HF, heart failure; LOX, lysil oxidase; TGF-b1, transforming
growth factor-b1.
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nonpharmacological and pharmacological interventions, as
well as novel cell and gene therapies, chronic HF still
continues to be a major cause of morbidity and mortality.
Here we show for the first time that local heart E2 is
significantly reduced in HF. Furthermore, cardiac aromatase
transcripts were also downregulated in HF, while remaining
unchanged in plasma (Figure 1). Despite the presence of
sustained pressure overload, pharmacological intervention
using E2 therapy after the onset of HF restored ejection
fraction of TAC-induced HF from 35% to 55% both in
male and female mice (Figures 2 and 3). E2 therapy also
restored heart E2 and aromatase transcript levels. Starting
E2 treatment after the establishment of HF has major
clinical advantages over previous studies that used E2
therapy prior to the initiation of the disease.5 As HF is not
often diagnosed early, our approach is more practical for
patients who already suffer from HF. E2-induced rescue of
HF is strongly correlated with stimulation of LV angiogen-
esis, as the angiogenesis inhibitor TNP-470 prevented
the beneficial action of E2 (Figure 5). In addition, the
beneficial effects of E2 in HF were also associated with the
reversal of myocardial fibrosis (Figure 6). E2-induced rescue
of HF was also associated with upregulation of phospho-
Akt as well as activation of estrogen receptor-b (Figures 8
and 9).
Regulation of Cardiac E2 and Aromatase in HF
Here we show that cardiac E2 levels are reduced in HF while
plasma E2 remains the same (Figure 1). Interestingly, aro-
matase transcripts are also reduced in HF; therefore, reduced
cardiac E2 could be caused by a reduction in aromatase levels,
a lower uptake of plasma E2 by cardiac tissue, or because of
impaired myocardial perfusion as a result of decreased
capillary density. Most importantly, E2 therapy restored cardiac
E2 levels as well as cardiac aromatase transcripts. The
normalization of cardiac aromatase transcripts by E2 therapy
could be result of improved heart function or attributable to
increased E2 availability in the heart. E2 therapy could directly
normalize aromatase transcripts by binding to a half ERE site, or
indirectly through transcription factors as our analysis of the 5-
kb promoter region of aromatase gene shows several half ERE
as well as Sp1 and Ap1 elements.
The role of aromatase in the heart is not well understood.
In postmenopausal women, aromatase plays an important
Figure 8. E2 therapy regulates Akt, but not Stat3 phosphory-
lation. A, Representative Western blot for whole heart lysates for
(A) Stat3 and phospho-Stat3 and (C) Akt and phospho-Akt. All the
samples in each experiment were blotted on the same Western
blot; some intervening lanes are not shown as the figure depicts 2
representative lanes/group. B and D, Bar graphs representing the
quantification of fluorescent signal of phosphorylated protein
expression as normalized to the corresponding total protein
expression and then to the corresponding loading control (GAPDH
for phospho-Stat3 and Vinculin for phospho-Akt) and to CTRL
levels. GAPDH and Vinculin were used as loading control.
*P<0.05 vs CTRL and ^P<0.05 vs HF (n=3–5 hearts/group).
CTRL indicates control; E2-RES, estrogen rescue; HF, heart failure. Figure 9. E2 therapy upregulates ERb protein levels. A, Relative
mRNA transcript levels normalized to CTRL. GAPDH was used as
an internal control. Representative Western blot of whole heart
lysates for (B) the 45- and 66-kDa isoforms ERa, and ERb. C, Bar
graphs representing the quantification of fluorescent signal of
ERa or ERb normalized to the corresponding Vinculin and to
CTRL. Vinculin was used as a loading control. *P<0.05 vs CTRL
and ^P<0.05 vs HF (n=4–5 hearts/group). CTRL indicates control;
E2-RES, estrogen rescue; ER-a/b, estrogen receptor-a/b; HF,
heart failure.
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role, as its peripheral activity becomes the primary source of
E2 synthesis.16 The ablation of aromatase has also been
demonstrated to be associated with increased adiposity17 and
progressive insulin resistance,18,19 which play significant roles
in the development of cardiovascular diseases such as
atherosclerosis and diabetic cardiomyopathy. Therefore,
restoring aromatase in the heart by E2 therapy could be an
important process in preserving the heart function.
Stimulation of Cardiac Angiogenesis by E2
Increased cardiac angiogenesis has been shown to be a key
event in maintaining LV function during adaptive hypertrophy
induced by pressure overload; however, the imbalance
between cardiac growth and neoangiogenesis eventually
leads to the transition from compensated heart hypertrophy
to HF.11 VEGF is an important angiogenic factor and a critical
determinant of capillary growth and density.20 We have shown
that E2 strongly stimulated VEGF expression and growth of
blood vessels in the LV of HF mice (Figure 5). The fact that E2
failed to rescue HF in the presence of the angiogenesis
inhibitor TNP (Figure 5D) strongly supports the critical role of
angiogenesis in the rescue action of E2. We also show that E2
can stimulate angiogenesis in healthy mice, in the absence of
TAC (Figure 6). This is not surprising as E2 has been shown to
be pro-angiogenic in various tissues and organs such as the
uterus, breast, brain, and limbs.21–24 However, the 30%
increase in angiogenesis in healthy mice that did not undergo
TAC is not as dramatic as the 300% observed in HF mice
treated with E2. Since the existing angiogenesis meets the
demands of the heart under basal conditions (in the absence
of TAC), there is only a marginal increase in angiogenesis by
E2. In HF, despite the larger left ventricle size and obvious
need for more blood vessels to support the heart muscle,
Table 2. E2 Therapy Restores Cardiac Function
CTRL HF E2-RESC
15 mice 25 mice 16 mice
IVS, mm
Diastolic 0.580.01 0.980.04** 0.940.07**
Systolic 0.900.03 1.080.06* 1.220.09*
LV PW, mm
Diastolic 0.560.01 1.050.05** 0.970.08**
Systolic 0.870.02 1.180.06** 1.290.08**
LV diameter, mm
Diastolic 4.570.08 4.440.09 4.660.12
Systolic 3.060.06 3.740.08** 3.390.11*^
LV volume, mm3
Diastolic 93.55.49 91.04.47 101.96.10
Systolic 362.53 60.93.35* 48.33.54*
LV %EF 61.50.74 33.21.13** 53.11.3**^^
LV %FS 330.53 15.70.58** 27.30.84**^^
10 mice 7 mice 7 mice
LVSP 104.73.9 95.65.5 1354.6**^^
LVEDP 6.93.8 9.54.9 42
LVDP 97.82.66 86.22.7* 1314.6**^^
RPP 60 868.62412.8 36 251.93531.7** 65 4555533.2^^
(dP/dt)Max 11 036.6495.2 4871.4511.9** 8541.2638.5*^^
(dP/dt)Min 8390.9469.3 4429.2280.1** 7862.6754.9^^
HR 622.819 421.740.4** 499.235.1
Values are meanSEM. Intraventricular septum (IVS), LV posterior wall (LV PW), LV chamber dimensions, and LV mass were obtained from M-mode images of parasternal short axis view
similar to those shown in Figure 2A.The number of animals is given in each section. CTRL indicates control; (dP/dt)Max, maximum rate of LV pressure rise; (dP/dt)Min, maximum rate of LV
pressure decline; E2-RESC, estrogen rescue; HF, heart failure; HR, heart rate; LV %EF, left ventricular ejection fraction; LV %FS, left ventricular fractional shortening; LVDP, left ventricular
developed pressure; LVEDP, left ventricular end-diastolic pressure; LVSP, left ventricular systolic pressure; RPP, rate pressure product.
*P<0.05 vs CTRL; **P<0.001 vs CTRL; ^P<0.05 vs HF and ^^P<0.001 vs HF.
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angiogenesis is drastically decreased. Therefore, the 300%
increase in neoangiogenesis by E2 therapy is a vital process in
restoring the heart function.
Furthermore, angiogenesis has been shown to play an
important role in maintaining cardiac health, since insufficient
blood flow could result in aggravating ischemic heart disease.
Many studies have shown that induction of new vessel growth
via many angiogenic factors including vascular endothelial
factor A (VEGFA), fibroblast growth factor-2, angiopoietin-2, or
stem cell therapy can improve cardiac function in various
animal models of heart disease.25,26 In this study, we have
highlighted the pivotal role played by E2 in rescuing HF. We
have demonstrated that E2 therapy results in a vast increase
in angiogenesis, thus reinforcing the concept that estrogen-
driven angiogenesis may play a critical role in improving
cardiac function. We have also shown that blocking angio-
genesis by using the angiogenesis inhibitor TNP together with
E2 treatment does not improve cardiac function, further
demonstrating a potential role of angiogenesis in the devel-
opment of HF.
Reverse Remodeling of Cardiac Fibrosis by E2
Therapy
End-stage HF has long been regarded as a terminal state of
cardiac pathological remodeling, consisting of fibrosis and
extracellular matrix remodeling that are almost impossible to
reverse by any currently available therapy. E2 treatment has
been demonstrated to mitigate adverse extracellular matrix
remodeling in LV hypertrophy and failure by decreasing
collagen deposition and metalloproteinase expression.27 Here
we show that E2-induced rescue of HF is associated with
reversal of LV fibrosis by reversing increased expression of
the profibrotic genes collagen I, III, transforming growth
factor-b1, lysil oxidase, and fibrosin I (Figure 7). Although
attenuation of fibrotic deposition in the heart with tetrahy-
drobiopterin (a NOS coupler), tempol (a broad antioxidant), as
well as FTY-720 (an immunomodulator for treating multiple
sclerosis28) in the TAC model has been demonstrated, our
study reports the reversal of extensive fibrosis with E2
therapy.
The Involvement of Akt and Estrogen Receptor-b
in the Rescue Action of E2
Previous findings by Weinberg et al9 showed that SERCA
mRNA levels were depressed 40% in male, but not in female
rats with ascending aortic stenosis–induced LV hypertrophy
as compared with control rats. Here we show that SERCA
transcript levels were also significantly downregulated in HF
and partially restored by E2 (Figure 4), thus indicating the
protective role of E2 via SERCA activation in this model of
pressure overload as well. Previous work by Patten et al29
further showed that estrogen pretreatment decreased Stat3
activation up to 48 hours post-TAC. In our model, however,
we do not see any significant differences in Stat3 activation in
HF or following E2 treatment (Figure 8). Because the mech-
anism by which E2 influences the activation of the Stat
transcription factor family has not yet been elucidated in
cardiomyocytes,29 it is possible that its regulation occurs only
early on post cardiac insult and its activation stabilizes after
more prolonged periods of time such as in our model.
Lastly, we investigated whether E2 can exert its cardio-
protective effect via Akt activation. We show that Akt
phosphorylation is reduced approximately by half in HF, while
E2 therapy normalized phospho-Akt expression to control
levels (Figure 8). These data are in agreement with previous
studies that reported a pressure overload–induced decrease
in Akt phosphorylation,13,14 which was significantly restored
by estrogen.14
Estrogen mainly acts through its classical receptors ERa
and/or ERb, and both receptors are present in the heart.15
The beneficial role of ERb in cardioprotection has been
Figure 10. E2 therapy restores systolic function
and corrects contraction and relaxation defects
induced by HF. A, RPP and (B) dP/dtMax (filled bars)
and dP/dtMin (open bars). The values and the
number of animals are given in Table 2. *P<0.05 vs
CTRL; **P<0.001 vs CTRL; ^^P<0.001 vs HF;
§P<0.05 vs E2; §§P<0.001 vs E2. CTRL indicates
control; E2-RESC, estrogen rescue; HF, heart fail-
ure; RPP, rate pressure product.
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highlighted in recent years,30 as it has been shown to be
responsible for the antihypertrophic and antifibrotic effects of
E2.5,30 Here we show that E2 therapy upregulated ERb
expression by 20%, which could also be one of the
mechanisms through which E2 rescues HF.
The Beneficial Action of E2 on the Heart
Our data show that E2 therapy restores systolic function and
corrects contraction and relaxation defects associated with
HF in spite of the sustained presence of the TAC banding
(Figure 10A and 10B). These hemodynamic data, together
with stimulation of cardiac angiogenesis by E2 (Figure 6) and
reversal of LV fibrosis (Figure 7), support the view that the
improvement of LV function is mediated via the action of E2
on the heart. However, the direct action of E2 on the vessel
wall could not be excluded, as E2 promotes vasodilation by
acting on the endothelial and smooth muscle cells.31 E2
directly stimulates endothelial nitric oxide synthase activity
and thus has a beneficial effect on vasculature. Many reports
have shown that E2 can cause arterial dilation of elastic and
muscular arteries in vivo via estrogen receptor–mediated
activation of ERK and PI3K, and stimulation of nitric oxide
production.32 Furthermore, E2 has also been shown to
promote dilation of canine coronary arteries in an endothe-
lium-independent manner not mediated by the classic intra-
cellular ERs;33 thus, unloading of the heart may be an
important explanatory factor for the rescue effect of E2
therapy. Therefore, it is possible that vasodilation caused by
E2 on the vessel wall has an additional contribution to the
observed E2-induced rescue of HF and results in beneficial
effects on cardiovascular function and improved cardiac
hemodynamics.
We have also found that treatment with E2 increases the
LV diameter and the LV volume compared to CTRL, suggesting
a dilatation of the LV as compared to CTRL. An elevation of
LVEDP is usually associated with an increase in LV diameter.
In our findings, however, we did not observe an increased
LVEDP after E2 treatment. On the contrary, we obtained a
reduction in the filling pressure compared to CTRL. Since the
HR is not statistically significant between the E2-treated and
CTRL groups, the elevated LVSP observed in the E2 group can
be undoubtedly associated with a Starling effect caused by a
much higher relaxation of the myocardium. Together, our
hemodynamic results indicate that after decompensated HF,
E2 treatment rescues the heart function by increasing the
myocardial relaxation, which favors the myocardial contrac-
tility.
Here we show that E2 rescues HF induced by pressure
overload both in male and female mice. In ovariectomized
rats, E2 replacement 2 weeks postaortic banding has been
shown to significantly inhibit pressure overload–induced
increases in heart hypertrophy and to ameliorate impairment
of LV function.14 Therefore, we speculate that E2 therapy
should improve cardiac function of OVX mice with HF as well.
The beneficial action of estrogen is not limited to only
pressure overload induced by TAC. Estrogen has been shown
to be protective in other models of HF such as ischemia/
reperfusion injury,34 volume overload,35 as well as right
ventricular failure secondary to pulmonary hypertension.36
We also show that E2-induced rescue of HF is associated
with the reversal of adverse LV remodeling. The beneficial
effects of E2 treatment in HF seem to result from an interplay of
different factors, among which restoration of cardiac aro-
matase levels, stimulation of cardiac neoangiogenesis, and
reversal of fibrosis are key mechanisms. However, the long-
term benefits of E2-induced cardioprotection in HF remain to be
evaluated, as it is yet unknown whether the beneficial effects of
short-term E2 therapy persist after E2 withdrawal. Further-
more, the mechanism of E2 action (genomic versus nonge-
nomic) also remain to be determined. Here we speculate that
E2-induced cardioprotection is via a genomic pathway, as E2
exerts its beneficial effects on the heart in 10 days.
Even though E2 may have unwanted long-term side effects,
our findings with relatively short-term E2 treatment raise the
exciting possibility to expand the application of E2 for the
treatment of chronic HF within a relatively safe time frame, a
concept that most definitely warrants further investigation.
Because E2 reverses LV dysfunction associated with a
number of cardiovascular diseases, our findings have broad
clinical implications.
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